INS and Insulin resistance: As GCs decrease peripheral insulin sensitivity, increase hepatic gluconeogenesis, trigger insulin resistance on the level of the lipid metabolism and adipose tissue, as well as inhibit pancreatic insulin production and secretion, they represent a drug class with the highest risk of provoking the development of hyperglycaemia and overt diabetes mellitus (DM) [3,4,5].